Search Results - "Boneva, Neli"

Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program by Cummings, Jeffrey L, Atri, Alireza, Ballard, Clive, Boneva, Neli, Frölich, Lutz, Molinuevo, José Luis, Raket, Lars Lau, Tariot, Pierre N

“…Globalization of clinical trials has important consequences for trial planning and interpretation. This study investigated heterogeneity in patient…”
Get full text

Major pathogenic effects of anti-MuSK antibodies in Myasthenia Gravis by Boneva, Neli, Frenkian-Cuvelier, Melinee, Bidault, Jocelyne, Brenner, Talma, Berrih-Aknin, Sonia

“…MG with anti-MuSK antibodies (MuSK+) is often characterized with muscle atrophy and excellent response to plasma exchanges. To elucidate some MuSK+ MG…”
Get full text

Stimulated-single fiber electromyography monitoring of anti-sense induced changes in experimental autoimmune myasthenia gravis by Boneva, Neli, Hamra-Amitay, Yasmine, Wirguin, Itzhak, Brenner, Talma

“…The neuromuscular weakness associated with myasthenia gravis (MG) can be transiently relieved by pharmacological inhibitors of acetylcholinesterase (AChE)…”
Get full text

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials by Atri, Alireza, Frölich, Lutz, Ballard, Clive, Tariot, Pierre N, Molinuevo, José Luis, Boneva, Neli, Windfeld, Kristian, Raket, Lars L, Cummings, Jeffrey L

“…IMPORTANCE: New therapeutic approaches for Alzheimer disease (AD) are needed. OBJECTIVE: To assess whether idalopirdine, a selective 5-hydroxytryptamine-6…”
Get full text

ALLEVIATE, a Clinical Trial-in-Progress of Eptinezumab in Patients With Episodic Cluster Headache (P3-2.002) by Tepper, Stewart J., Boneva, Neli, Josiassen, Mette Krog, Löf, Elin, Jensen, Rigmor Hoejland

“…Abstract only…”
Get full text

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease by Herrmann, Nathan, Gauthier, Serge, Boneva, Neli, Lemming, Ole Michael

“…Agitation and aggression in Alzheimer's disease (AD) are amongst the most serious of neuropsychiatric symptoms, and contribute to poor outcomes and worse…”
Get more information

Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease by Frölich, Lutz, Atri, Alireza, Ballard, Clive, Tariot, Pierre N, Molinuevo, José Luis, Boneva, Neli, Geist, Marie A, Raket, Lars L, Cummings, Jeffrey L

“…This open-label extension study evaluated the long-term safety and tolerability of idalopirdine 60 mg/day as adjunctive therapy in patients with mild-moderate…”
Get more information

P3‐003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS by Ballard, Clive, Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L., Frölich, Lutz, Molinuevo, José Luis, Raket, Lars Lau, Tariot, Pierre N.

Get full text

IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER’S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS by Ballard, Clive, Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L., Frölich, Lutz, Molinuevo, José Luis, Raket, Lars Lau, Tariot, Pierre N.

Get full text

P1‐056: Idalopirdine, A 5‐HT6 Antagonist in Phase III Development as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild‐to‐Moderate Alzheimer’s Disease: Baseline Data from the Ongoing Starshine Study by Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L., Frölich, Lutz, Tariot, Pierre N., Windfeld, Kristian

Get full text

IDALOPIRDINE, A 5-HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’S DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM by Atri, Alireza, Frölich, Lutz, Ballard, Clive, Tariot, Pierre, Molinuevo, José Luis, Boneva, Neli, Windfeld, Kristian, Cummings, Jeffrey L.

Get full text

IDALOPIRDINE, A 5-HT6 ANTAGONIST IN PHASE III DEVELOPMENT AS ADJUNCTIVE THERAPY TO CHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE: BASELINE DATA FROM THE ONGOING STARSHINE STUDY by Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L, Frölich, Lutz, Tariot, Pierre N, Windfeld, Kristian

Get full text

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease by Ballard, Clive, Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L., Frölich, Lutz, Molinuevo, José Luis, Tariot, Pierre N., Raket, Lars Lau

“…Heterogeneity of outcomes in Alzheimer's disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis…”
Get full text

The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis by Brenner, Talma, Hamra‐Amitay, Yasmine, Evron, Tama, Boneva, Neli, Seidman, Shlomo, Soreq, Hermona

“…Alternative splicing induces, under abnormal cholinergic neurotransmission, overproduction of the rare “readthrough” acetylcholinesterase variant AChE‐R. We…”
Get full text

Gabapentin may be hazardous in myasthenia gravis by Boneva, Neli, Brenner, Talma, Argov, Zohar

“…A patient with painful neuropathy developed ocular, facial, and masticatory weakness and fatigue after 3 months of gabapentin (GBP) treatment (400 mg/day). An…”
Get full text